Entrepreneurs in Residence
Paul F. Brown holds the James Lee Sorenson Presidential Chair and is a Professor of Entrepreneurship and Strategy at the David Eccles School of Business. He has over 20 years of healthcare and healthcare investing experience. In addition to teaching, Paul is an Advisory Partner with Granite Growth Health Partners, a healthcare services venture capital fund. He serves on the boards of or advises CleanSlate Centers (multi-site outpatient addiction treatment), Central Logic (patient flow software for health systems), QualDerm Partners (multi-site professional dermatology practice management), Advantia (multi-site women’s health), and Vytalize Health (senior primary care).
He has served as a volunteer judge or mentor for Healthbox, Village Capital, The American Dream Ideas Challenge, and Bench2Bedside. Paul is an active angel investor. Prior to teaching, he co-founded and co-managed the $300 BlueCross Blue Shield Venture Partners healthcare fund. He was also a managing director of Sandbox Industries, a Chicago-based venture capital firm. Prior to that, Paul was a vice president in the national Blue Cross and Blue Shield organization for ten years. Previously, he practiced law at the Chicago office of Kirkland & Ellis LLP for ten years, where he was a partner. Paul earned his undergraduate degrees from the University of Utah and a law degree from the Northwestern University Pritzker School of Law.
Dr. Gregory Critchfield received a Bachelor’s Degree in Microbiology from Brigham Young University in 1976, an MD degree from the University of Utah in 1980, and a master’s degree in Biophysical Sciences at the University of Minnesota in 1985. He served as a reviewer and study section chair for the NIH for 15 years in biomedical computing programs for SBIR, STTR and R01 programs. His research spans a number of areas in laboratory medicine, with recent work in clinical genetics and proteomics. He has served on the medical school faculty of the University of Minnesota, Wayne State University and Duke University. He served as Chief Medical and Science Officer of Quest Diagnostics from 1995-1998. He joined Myriad Genetics, Inc. in 1998, where he was President of its diagnostic subsidiary, Myriad Genetic Laboratories, Inc. until 2010, where he built Myriad Genetic Laboratories, Inc. into one of world’s leading molecular diagnostic companies. He chaired the Governor’s State Advisory Council on Science and Technology for the state of Utah in 2007. He has served and is serving as an independent director in industry association and various life science companies developing breakthrough diagnostic technologies and tests. He currently serves as Chairman and CEO of Sera Prognostics, Inc., a women’s health company focusing on preterm birth diagnostics, where the company has raised more than $85M in venture funding since 2011. He also serves as a Trustee of Bear Lake Watch.
Dr. Davidson is a practicing orthopedic surgeon with a particular interest in Cartilage Restoration and Joint Resurfacing. He has a background in Sports Medicine and has engaged extensively in teaching, research and product development throughout his career. He has served as a consultant or director for an array of companies including large and small medical device firms, biomaterials, orthobiologic, tissue allograft and cell therapy companies. He has worked with publicly traded, privately held and start-up entities. He is the Medical Director of UtahOSIC, a comprehensive medical clinic rendering care to accident victims. He is the co-founder of IdeaMD, a company that evaluates and launches med device technologies. Dr. Davidson is the CEO of the first portfolio company from IdeaMD, Coracoid Solutions, LLC which is commercialized its product line in Q4 2017.
James has founded and helped launch a number of highly valued start-ups including: General Surgical Innovations, Inc. (acquired by Tyco Healthcare in 1999), Embolic Protection, Inc. (acquired by Boston Scientific in 2001), HotSpur Technologies (acquired by Teleflex in 2012), Access Closure (acquired by Cardinal Health in 2014) and both Axiom Technology Partners & Atsina Surgical (Axiom was acquired in 2012 and Atsina in 2015). When James is not playing hockey, baseball, or basketball with his son Dash, he also serves as an Industry Mentor & Advisor to UCLA’s MedTech Innovations Program. Prior to his entrepreneurial career, James held various US and International Senior Management positions at Johnson & Johnson and Baxter Healthcare. James has authored and co-authored a number of patents and patent applications. He attended the Sorbonne University in Paris and obtained a Bachelor of Arts degree from Wabash College, where he also serves on the College's Advisory Board for The Center for Innovation, Business, and Entrepreneurship (CIBE).
SHAWN P. FOJTIK
Shawn Fojtik is co-founder of Distal Access, Control Medical, CIRCA Scientific, Pinyons, and others with sales, training, and marketing experience at GE Medical, Boston Scientific, and Black & Decker.
His experience includes devices for cardiology, interventional radiology & oncology, electrophysiology, surgery, enteral feeding, and other procedures and has closed transactions with Boston Scientific, Covidien, Mallinckrodt, Medtronic, Merit Medical, Teleflex, and others.
Control Medical’s award-winning patented platform is used to remove blood clots during acute myocardial infarction (AMI), peripheral vascular disease, deep vein thrombosis (DVT), and ischemic stroke. Control has one of the largest FDA cleared platforms in the United States and has been used in 10,000+ procedures.
Shawn has 50+ combined issued and pending global patents; has been a speaker/ author/contributor/research contributor at Heart Rhythm Society, Cardiovascular Research Technologies, and other conferences; and has a BS from the University of Illinois and a MA from Harvard University.
Dr. Myles Greenberg comes to Alucent Biomedical with more than 20 years of experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor. Prior to joining Alucent, he served as chief development officer at IntegraMed America, a private equity backed healthcare services firm. Previously, Dr. Greenberg spent most of his career as an early-stage venture capital investor with CHL Medical Partners, HealthInvest Equity Partners and Pappas Ventures. As a start-up venture investor and board member, he often served as lead director or in an interim management role at many dynamic companies in the biotechnology, medical device, and healthcare services sectors.
In addition to leading the Alucent team, Dr. Greenberg currently serves on the board of directors of Urgent Care Centers of New England (d/b/a CareWell Urgent Care), a company he co-founded, and as Entrepreneur-In-Residence at the University of Utah Center for Medical Innovation. Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center / Harvard Medical School in Boston. He holds a Master of Business Administration from Harvard Business School, Doctor of Medicine from Yale University School of Medicine and a Bachelor of Applied Science from the University of Pennsylvania School of Engineering and Applied Science and is a Diplomate of the American Board of Emergency Medicine.
Ron has over 25 years of hands-on experience in executive leadership, sales, strategy, finance and capital raising for companies at every stage of the business cycle and across industry verticals. A serial entrepreneur, angel investor and licensed investment banker, Ron brings a well-rounded, balanced perspective to solving any business challenge.
Currently, Ron is General Partner of Mountain Pacific Venture Fund, a VC fund investing in early-stage biotech and life sciences companies in the Mountain West and in South Korea. In 2014, Ron co-founded Church & State, a 501(c)(3) nonprofit dedicated to creating a sustainable entrepreneur ecosystem and business incubation platform. He is also Managing Partner of LDD, a boutique strategic management consulting and angel investing firm focused on biotech and life sciences.
Previously, Ron served as CEO of multiple technology and web development companies, most notably Lead Dog Design, an award-winning web development firm that served numerous Fortune 500 clients. Under his leadership, the company experienced 100% growth for three straight years, earning Ron recognition as one of Ernst & Young’s top entrepreneurs. Lead Dog Design was acquired by Iconixx Corporation, a top 10 media development firm. After the dot-com bubble, Ron spearheaded the reacquisition of Lead Dog Digital, returning the company to profitability as its President/CEO and, ultimately, its Chairman, before it was acquired by Bridgeline Software [NASDAQ: BLIN].
Dr. Jones joined BD in April 2012 as the World Wide Director of Infusion Therapy at the Sandy, Utah facility. Previously he served as the Chief Medical Officer for Coherex Medical, a structural heart device developer. Prior to this he worked as a Medical Director for the Vascular Protection, Vascular Imaging, Electrophysiology, and Endoscopy business units at Boston Scientific. He also served as Medical Director for Rubicon Medical developing an Embolic Protection device for carotid and coronary stenting. Prior to working in the medical device industry, Dr. Jones worked for more than 20 years in private practice as a general and vascular surgeon. Dr. Jones attended medical school at the University of Utah in Salt Lake City and completed his surgical training at Charity Hospital/Louisiana State University in New Orleans. He served as Chief Surgical Resident and acting Medical Director of Charity Hospital. He has received certification/recertification from the American Board of Surgery and is a Certified Nutrition Support Physician. During his years in private practice, Dr. Jones served as a physician consultant to Bard/Davol, Blue Cross/Blue Shield, Altius Healthplans, Realms of Inquiry School, and Edge Endurance Nutrition. He has also served as the Chairman of the Department of Surgery at Jordan Valley Hospital.
Dan Lemaitre joined BlueWind Medical, an Israel neuromodulation development company as Executive Chairman in September 2018. He also serves as Chairman of Endologix (NYSE: ELGX) a Irvine California company that is focused on aortic disorders with ~$150 million in annual sales and 650 employees. He is also on the board of Globus Medical (NYSE: GMED) one of the fastest growing spinal companies with revenue of ~$700 million per annum. Previously, Mr. Lemaitre was the CEO of CoreValve that launched the first commercial transcatheter aortic valve in Europe in 2007. By 2009 revenue were at a $100 million annualized run rate. Dan led negotiations that resulted in the sale of CoreValve to Medtronic in a transaction valued at $800 million. Prior to joining CoreValve, Mr. Lemaitre was a Senior Vice President at Medtronic where he headed-up strategic planning and corporate development. Earlier in his career Dan spent 28 years in the medical device field as an investment analyst.
19 consecutive years, capturing first place honors 8 times as the top-ranked medical device analyst in the country.
Dr. Ryan Lewis is a physician-executive recognized for his ability to create innovate solutions in the medical device arena. Dr. Lewis has held industry roles as product specialist, director of medical affairs, senior clinical director and chief medical officer for surgical oriented companies such as Megadyne Medical Products, W.L. Gore & Associates and Johnson & Johnson Ethicon. Combining a unique background of medicine/surgical training, product development experience and public health, Dr. Lewis has brought a valued perspective to strategic business innovation using his talents and skills to bring new products to market, support existing product lines and merger and acquisitions. Dr. Lewis has over 18 years of medical device industry experience with his most recent role providing support through the acquisition and integration of Megadyne Medical Products by Johnson & Johnson / Ethicon in 2017. Dr. Lewis provided a key role in preparing Megadyne as a competitive target by improving the customer experience and effectiveness of Megadyne products as well as creating new products enticing to prospective corporate buyers. As Chief Medical Officer, Dr. Lewis also served for over 10 years as one of three C-level executives on the executive board. Dr. Lewis also provided medical insight into safety and quality issues related to the potential and real use of medical devices. During this 10 year period, Dr. Lewis successfully executed four clinical studies intended for use by the sales force in evidence-based selling. One of the studies was a landmark multi-center study supporting the ACE Blade, a key technology relaunched by Johnson & Johnson this year and hailed as a great success.
Jay is an Operating Partner with the Med Venture Holdings group. He is currently President and CEO of Piper Access, LLC, a vascular access company and Talon Medical, LLC (DBA Talon Surgical), a heart access company. He has 27 years of experience in innovation, engineering, technology development, and commercialization. Jay is passionate about developing medical devices that are loved by both clinicians and patients. Prior to the Piper Access and Talon Surgical, Jay worked for GE, IOMEGA, BD, & BARD in the management of product innovation & technology development. Jay received his BS in Mechanical Engineering from Brigham Young University and his Masters in Mechanical Engineering from San Jose State University.
He currently resides in Salt Lake City, UT where he enjoys backcountry skiing and mountain biking.
Dr. Stephen Neeleman is the founder and vice chairman of HealthEquity. Steve founded HealthEquity in 2002, with the vision to repair the fractured relationship between patients and their physicians and to help more people obtain quality health insurance by re-introducing consumerism to health care. Steve is the co-author of The Complete HSA Guidebook—How to Make Health Savings Accounts Work for You. In addition to his duties as founder and vice chairman of HealthEquity, Steve was also a practicing general and trauma surgeon for Intermountain Healthcare at American Fork Hospital and Utah Valley Regional Medical Center until 2015. As a board-certified physician, Steve brings his passion and firsthand knowledge from the practice of medicine to his leadership role at HealthEquity. Steve was appointed by Utah’s Governor, Gary Herbert, to serve as a board member of HIP Utah, Utah’s high-risk insurance pool. He also serves on the Council for Affordable Health Insurance HSA Working Group, and on America’s Health Insurance Plans’ HSA Leadership Council. Steve completed his undergraduate degree and played football at Utah State University. He attended medical school at the University of Utah and completed his surgical training at the University of Arizona. Steve also served as an assistant professor of surgery at the University of Arizona.
Dr. Parks is Emeritus Professor of Neurobiology & Anatomy at the University of Utah School of Medicine. From 2008 until his retirement in 2016, he was Vice President for Research and President of the University of Utah Research Foundation. After training in neuroscience at the University of California, Yale University, and the University of Virginia, Dr. Parks joined the Utah faculty in 1978. His research on neurobiology of the developing auditory system was continuously funded by the National Institutes of Health for 26 years, he taught neuroscience to medical and graduate students for 30 years, and was chair of his department for 15 years.
Dr. Parks was a co-founder of NPS Pharmaceuticals Inc. and a board member from 1986-2006; the company developed three first-in-class drugs and was acquired by Shire Plc for $5.2 billion in 2015. He has also served as a board member or scientific advisor for several private companies (currently including ConusRx, Navigen Pharmaceuticals, Q Therapeutics, and SentrX Animal Care) and as a trustee or director for several non-profit organizations. He received a Claude Pepper Award from the National Institute on Deafness and Communicative Disorders in 1993, was elected as a Fellow of the National Academy of Inventors in 2013 and received a Utah Governor’s Medal for Science and Technology in 2015.
Dr. Patel is the co-founder and managing director of Aqua Recycling Group (2017) and founder and managing director of Patel Family Investments (2014) and co-founded vSpring Capital ($400 million under management) in 2000 and has been a founding managing director till October 2014.
He serves on several non-profit boards, and has won numerous awards including; 2013 Willem J Kolff Lifetime Achievement Award, the 2011 Father of the Year, 2010 Utah Youth Village Helping Hand Award, 2006 Utah Technology Council Hall of Fame Inductee, 2006 Ellis Island Medal of Honor, US Small Business Administration’s Business Achiever Award, Scientific and Technology Award (State of Utah), Entrepreneur of the Year Award (Mountain West Venture Group) and Scientific and Technology Development Pioneer of Progress Award to name a few. He is also a charter member of The Indus Entrepreneurs (TiE).
Kelly Powers, recently retired, was Vice President of Science and Technology for C.R. Bard Inc. in (Murray Hill, NJ). Prior the prior 14 years, Kelly served as Senior Vice President of Research and Development at Bard Access Systems, Inc. in Salt Lake City (a subsidiary of C. R. Bard). Over this time he also organized the largest and most successful internship program for engineering students in medical devices in Utah and created hundreds of engineering and other technical jobs in Utah and other states. Kelly’s holds with over 60 issued U. S. patents in medical devices and other technical areas and more than 200 additional international patents or patents pending; the most in Bard history. Cumulatively, products based on Kelly's patents have generated more than $8 Billion dollars in sales and improved the lives of countless patients and clinicians. In 2011, Kelly was awarded the Governor’s Medal for Science and Technology by Governor Gary Herbert and in 2017 BioUtah’s Lifetime achievement award for his body of work in Utah life sciences. In 2012, on behalf of a 14-state delegation, Kelly addressed both the United States Senate and House of Representatives subcommittees regarding the government’s role in innovation of medical devices. Kelly continues to be active in the health sciences field in the United States and abroad with advisory roles in start-ups and large medical device companies around the world. He resides in Utah with his wife Sandra.
Vrunda Rathod has extensive health policy experience. She started her career for U.S. Congresswoman Diane Watson as a legislative aide focusing on both national and global health care, foreign affairs, and environmental policy. She lead the Congresswoman’s global health policy, on issues including IP, foreign aid, and programmatic developments. When the Congresswoman retired, she decided to move back to California and spent time consulting for Kaiser Permanente, until an exciting opportunity in Liberia came along. She worked with the Clinton Health Access Initiative to research maternal and newborn deaths in the country. Her research helped the country win a grant that is focused on improving maternal care in the country. Upon returning from Liberia, she helped design and implement a program for ethical thinking in synthetic biology, called synbio LEAP. For the last three year, she was working to bring a low cost treatment for postpartum hemorrhage to low income countries at InPress Technologies. At InPress she led the global marketing, working to understand users and their interaction with the InPress product. She is currently an independent marketing consultant for a number of global health medtech companies. Vrunda holds an undergraduate degree from USC in Biomedical Engineering and a graduate degree in Biomedical Science Policy from Georgetown University.
Mr. Thayne is a partner and co-founder of Thayne & Davis LLC, a law firm focused on intellectual property and related disputes, including patents, trademarks, intellectual property due diligence, intellectual property litigation, product development and design arounds, and written opinions and analysis regarding patent and other intellectual property matters, including freedom to operate, patentability, patent validity, patent enforceability, and patent infringement. Mr. Thayne started his legal career at Stoel Rives, where he was a partner in the Technology and Intellectual Property practice group. He has an undergraduate degree from the University of Utah in physics, where he graduated summa cum laude. He also graduated from the S.J. Quinney College of Law at the University of Utah where he graduated Order of the Coif. Mr. Thayne has been selected as one of "America's Leading Lawyers for Business" by Chambers USA, as one of Utah's "Legal Elite" for intellectual property law, and as a "Rising Star" among intellectual property attorneys by Super Lawyers magazine.
Wm. Dean Wallace, obtained an MD and PhD from the University of Utah, then founded several medical companies that grew and were successfully sold to larger companies. He recently started a new company, Liger Medical LLC. (www.curemedicalglobal.com), which focuses on treang pre‐cancerous lesions of the cervix with the hope to eradicate cervical cancer world-wide.
He was previously the President, CEO, of Clinical Innovaons, Inc., Murray, and Utah Medical Products, Inc., a clinical assistant professor at the University of Utah, and is listed as inventor on over 20 medical patents related to women’s healthcare medical devices. He is happily married, and the father of four children and 12 wonderful grandchildren.